drugset
drugset / Trial / NCT05005273

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

NCT05005273 ↗

Phase 2 Completed 1 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).

Timeline

Start
2022-10-03
Primary completion
2022-12-27
Completion
2022-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject RENVISTOBART Monoclonal antibody — —
Background Ipilimumab Monoclonal antibody — —
Background Nivolumab Monoclonal antibody — —

Indications

non-small cell lung carcinoma